CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal Malik, MB BS, to its Board of Directors. Dr. Malik, who is currently a member of the Board of Management of Bayer AG, will officially join the Acceleron Board effective January 1, 2020.
“We’re thrilled to be able to add an individual of Kemal’s caliber to the Acceleron Board,” said Francois Nader, M.D., Chairman of Acceleron Pharma. “His global development and innovation experience across a range of therapeutic areas should prove enormously valuable in helping to guide Acceleron through its exciting transition from a clinical-stage organization to a fully-integrated biopharmaceutical company.”
Dr. Malik has served on the Board of Management of Bayer AG since 2014, with responsibility for Innovation across the Bayer group. His career at Bayer began in 1995 as Head of Metabolic Medicine and Oncology for Europe. He later served as Head of Global Medical Development, before being appointed in 2004 as Head of Global Development and Chief Medical Officer as well as a member of the Executive Committee of Bayer HealthCare AG. Dr. Malik received his medical qualification from the University of London.
“It’s a privilege to join the Board of Acceleron,” said Dr. Malik. “Having spent considerable time pursuing innovation at Bayer, I’m delighted to be associated with a company dedicated to delivering first-in-class approaches to patients who have long been in need of new therapeutic options.”
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.